Palatin Technologies (PTN) Stock Price, News & Analysis

Company Overview

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.

Key Stats

• Today's Range: $0.09 to $0.11
• 50-Day Range: $0.09 to $0.23
• 52-Week Range: $0.09 to $2.48
• Volume: 14.57 million shs
• Average Volume: 2.28 million shs
• Market Capitalization: $2.45 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PTN Stock Analysis - Frequently Asked Questions

How have PTN shares performed this year?

Palatin Technologies' stock was trading at $0.22 at the beginning of 2025. Since then, PTN shares have decreased by 57.2% and is now trading at $0.0941.
View the best growth stocks for 2025 here.

Who are Palatin Technologies' major shareholders?

Top institutional shareholders of Palatin Technologies include Armistice Capital LLC (6.43%).
View institutional ownership trends.

How do I buy shares of Palatin Technologies?

Shares of PTN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Manufacturing
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:PTN
• CIK: 911216
• Web: N/A
• Phone: (609) 495-2200
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $350 thousand
• Price / Sales: 6.99
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 26,006,000
• Free Float: N/A
• Market Cap: $2.45 million
• Optionable: N/A
• Beta: 0.94